Affinage

CDH13

Cadherin-13 · UniProt P55290

Length
713 aa
Mass
78.3 kDa
Annotated
2026-06-09
100 papers in source corpus 22 papers cited in narrative 22 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CDH13 (T-cadherin/H-cadherin) is an atypical GPI-anchored cadherin that lacks transmembrane and cytoplasmic domains and signals from the cell surface to control proliferation, adhesion, apoptosis, metabolism, and vascular biology (PMID:11642747). In tumor cells it behaves as a pro-apoptotic suppressor: re-expression antagonizes AKT/CREB/AP-1/FoxO3a signaling, downregulates BCL-2, BCL-xL, and Clusterin, and sensitizes melanoma cells to CD95/Fas-mediated apoptosis (PMID:23625515), while in bladder carcinoma loss of CDH13 promotes migration, invasion, and adhesion through upregulation of MMP2 (PMID:23235385). Consistent with a tumor-suppressor role, CDH13 is silenced across breast, lung, and squamous cancers primarily by promoter CpG hypermethylation, reversible with demethylating agents (PMID:11389090, PMID:12177241), reinforced by combined methylation/histone-deacetylation through a UHRF1/PRMT5 axis (PMID:26597461) and opposed by Pol β-dependent promoter demethylation that restores its anti-migratory activity (PMID:32641859); expression is further controlled by direct transcriptional repression via BRN2 (PMID:23069940) and by post-transcriptional regulation through miR-377 and the lncRNA CDH13-AS2 (PMID:29771432). As an endothelial receptor, CDH13 sequesters HMW adiponectin and is required for adiponectin-dependent suppression of airway and ozone-induced IL-17A inflammation (PMID:22815927, PMID:23755285), and it participates in pathological vascular remodeling and neovascularization via NF-κB and MyD88 signaling (PMID:38278560, PMID:41814412). CDH13 also localizes to pancreatic β-cell insulin granules and is required for second-phase glucose-stimulated insulin secretion (PMID:21975561), and supports adipogenesis by promoting fatty acid uptake and PPARγ/C/EBPα induction (PMID:29467502). In the nervous system CDH13 negatively regulates EGF-driven neuronal proliferation (PMID:10737605) and shapes excitatory/inhibitory balance and serotonergic neuron migration relevant to fear and stress behavior (PMID:30165120).

Mechanistic history

Synthesis pass · year-by-year structured walk · 21 steps
  1. 2000 Medium

    Established the first functional role for CDH13, showing it restrains growth-factor-driven proliferation rather than acting purely as an adhesion molecule.

    Evidence Gain-of-function transfection of T-cadherin into negative neuroblastoma cells with EGF proliferation assay

    PMID:10737605

    Open questions at the time
    • Mechanism by which the GPI-anchored ectodomain blocks EGF mitogenic signaling not defined
    • Single cell-line context
  2. 2001 Medium

    Defined the defining structural feature — a GPI anchor with no transmembrane or cytoplasmic domain — framing CDH13 as a signaling receptor that must act through partners.

    Evidence Biochemical/structural characterization reviewed

    PMID:11642747

    Open questions at the time
    • Does not identify the transmembrane co-receptors that transduce CDH13 signals
  3. 2001 High

    Identified promoter CpG hypermethylation as a direct, reversible silencing mechanism for CDH13 in cancer, explaining its frequent loss.

    Evidence Methylation-specific PCR and 5-aza-2-deoxycytidine demethylation rescue in breast and lung cancer cell lines

    PMID:11389090

    Open questions at the time
    • Enzymes establishing the methylation not identified here
    • Causal link to tumor phenotype not yet shown
  4. 2002 High

    Showed that methylation cooperates with loss of heterozygosity to fully inactivate CDH13 in invasive squamous carcinoma, supporting a two-hit tumor-suppressor model.

    Evidence LOH, MSP, demethylation rescue, IHC and Western blot in cutaneous SCC and A431 cells

    PMID:12177241

    Open questions at the time
    • Functional consequence of biallelic loss for invasion not directly tested
  5. 2011 High

    Revealed an unexpected metabolic role: CDH13 resides on insulin granules and is specifically required for second-phase glucose-stimulated insulin secretion.

    Evidence EM, live-cell colocalization, Tcad-KO mouse islet secretion assays and in vivo hyperglycemic clamp

    PMID:21975561

    Open questions at the time
    • Molecular role on the granule (docking vs trafficking) unresolved
    • Binding partner on granules not identified
  6. 2011 High

    Established CDH13 as the endothelial receptor that sequesters adiponectin, defining how it controls circulating adiponectin levels and allergic airway inflammation.

    Evidence T-cad KO and adiponectin/T-cad double-KO epistasis in OVA airway model with serum adiponectin ELISA

    PMID:22815927

    Open questions at the time
    • Downstream signaling from the CDH13-adiponectin complex not mapped
  7. 2012 High

    Identified BRN2 as a direct transcriptional repressor of CDH13, adding a methylation-independent silencing route in melanoma.

    Evidence Luciferase reporter, EMSA, BRN2 overexpression and knockdown in melanoma cells

    PMID:23069940

    Open questions at the time
    • Interplay between BRN2 repression and promoter methylation not resolved
  8. 2012 Medium

    Provided functional evidence that CDH13 suppresses cancer cell invasiveness through MMP2 regulation.

    Evidence siRNA knockdown in bladder TCC 5637 cells with migration/invasion/adhesion assays and MMP2 readout

    PMID:23235385

    Open questions at the time
    • Mechanism linking CDH13 loss to MMP2 induction unknown
    • Single cell line
  9. 2013 High

    Mapped the pro-apoptotic tumor-suppressor signaling of CDH13, showing it antagonizes AKT/CREB/AP-1/FoxO3a survival signaling and ruling out NFκB/mTOR involvement.

    Evidence Stable expression in melanoma, xenografts, pathway Western blots, reporter assays, CD95/Fas apoptosis assay

    PMID:23625515

    Open questions at the time
    • How the GPI-anchored ectodomain reaches intracellular AKT signaling is not defined
  10. 2013 High

    Demonstrated that CDH13 is the obligate mediator of adiponectin's suppression of ozone-induced IL-17A pulmonary inflammation.

    Evidence T-cad KO, Adipo KO, and double-KO epistasis with ozone exposure and IL-17A readouts

    PMID:23755285

    Open questions at the time
    • Cell type and signaling cascade linking endothelial CDH13 to IL-17A suppression not detailed
  11. 2013 Medium

    Tested whether ADHD-associated CDH13 missense variants disrupt protein processing, finding canonical GPI anchoring and localization unaffected.

    Evidence Expression of WT and mutant CDH13 in CHO/HEK293 with immunofluorescence

    PMID:23936508

    Open questions at the time
    • Negative result; functional consequence of variants on signaling not addressed
  12. 2015 Medium

    Linked a UHRF1/PRMT5 complex to CDH13 promoter methylation, indicating coordinated DNA and histone modification silences the gene.

    Evidence Co-IP of UHRF1-PRMT5 and combined 5-Aza-CdR/TSA rescue in endometrial carcinoma cells

    PMID:26597461

    Open questions at the time
    • Direct recruitment of UHRF1/PRMT5 to the CDH13 promoter inferred, not reconstituted
  13. 2018 Medium

    Showed CDH13 promotes adipocyte differentiation by enabling fatty acid uptake and PPARγ/C/EBPα induction, extending its metabolic function to lipid handling.

    Evidence CDH13 knockdown during 3T3-L1 differentiation with fatty acid uptake, lipid, and transcription factor readouts

    PMID:29467502

    Open questions at the time
    • No effect in mature adipocytes; receptor-level mechanism for lipid uptake unknown
  14. 2018 Medium

    Identified miR-377 as a direct post-transcriptional regulator of CDH13 in a neuronal disease model.

    Evidence Dual-luciferase 3'-UTR reporter and rescue assays in SH-SY5Y cells

    PMID:29771432

    Open questions at the time
    • Physiological relevance beyond the cell model unestablished
    • Single study
  15. 2018 Medium

    Defined CNS functions for CDH13 in excitatory/inhibitory balance, serotonergic neuron migration, and fear/stress behavior.

    Evidence Cdh13 KO mouse behavioral battery, hippocampal transcriptomics, cited electrophysiology

    PMID:30165120

    Open questions at the time
    • Electrophysiology not directly described
    • Molecular pathway in neurons not defined
  16. 2020 Medium

    Established that Pol β-driven base-excision-repair demethylation reactivates CDH13, with CDH13 mediating Pol β's anti-migratory and anti-angiogenic effects.

    Evidence Pol β overexpression/knockdown, methylation analysis, CDH13 siRNA rescue, xenografts in breast/lung cancer

    PMID:32641859

    Open questions at the time
    • BER-dependent demethylation inferred but not reconstituted in vitro
  17. 2024 Medium

    Implicated CDH13 in pathological vascular remodeling through interaction with MyD88, augmenting smooth muscle cell proliferation and ECM deposition.

    Evidence Molecular docking, Co-IP, SMC proliferation/migration/sprouting assays, carotid ligation mouse model

    PMID:38278560

    Open questions at the time
    • CDH13-MyD88 interaction from docking and single Co-IP without reciprocal validation
    • Single study
  18. 2024 Medium

    Showed CDH13 expression confers melanoma sensitivity to garcinol-induced apoptosis, linking its tumor-suppressor function to drug response.

    Evidence siRNA knockdown and garcinol treatment in melanoma cell lines with proliferation/apoptosis assays

    PMID:38791932

    Open questions at the time
    • Mechanism connecting CDH13 to garcinol response not defined
    • Single study
  19. 2024 Medium

    Demonstrated that restoring CDH13 via small activating RNA overcomes BCR-ABL1-independent imatinib resistance by inhibiting NF-κB and inducing apoptosis.

    Evidence saRNA targeting CDH13 promoter, viability/colony assays, NF-κB readout, LNP-saRNA xenograft in CML cells

    PMID:39179585

    Open questions at the time
    • How surface CDH13 modulates NF-κB not mechanistically resolved
  20. 2025 Medium

    Identified the lncRNA CDH13-AS2 as a stabilizer of CDH13 mRNA against miRNA-mediated decay and linked CDH13 loss to atherosclerosis.

    Evidence dCas13 RNA-IP, CRISPRa/KO in endothelial cells, miRNA screen, Cdh13/Apoe double-KO atherosclerosis model (preprint)

    PMID:40894025

    Open questions at the time
    • Preprint, not yet peer-reviewed
    • Mechanism of CDH13-AS2 protection of mRNA not detailed
  21. 2026 Medium

    Placed CDH13 in a hypoxia-NR2F2-NFκB axis driving pathological neovascularization, defining an upstream transcriptional regulator and therapeutic angle.

    Evidence CDH13 knockdown in OIR/CNV models, dual-luciferase NR2F2-CDH13 reporter, LXR agonist treatment, human FVM bioinformatics

    PMID:41814412

    Open questions at the time
    • How surface CDH13 activates NF-κB in endothelium not defined
    • Single study

Open questions

Synthesis pass · forward-looking unresolved questions
  • How a GPI-anchored cadherin lacking a cytoplasmic domain transduces signals to intracellular pathways (AKT/FoxO3a, NFκB, MyD88) across its many contexts remains the central unresolved question.
  • Transmembrane co-receptor(s) for CDH13 not identified
  • Unified signaling mechanism across cancer, metabolic, vascular, and neural roles not established

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060089 molecular transducer activity 3 GO:0098631 cell adhesion mediator activity 2 GO:0140313 molecular sequestering activity 2
Localization
GO:0005886 plasma membrane 2 GO:0031410 cytoplasmic vesicle 1
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-5357801 Programmed Cell Death 3 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-1430728 Metabolism 2
Partners
ADIPOQMYD88

Evidence

Reading pass · 22 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2000 CDH13 (T-cadherin) functions as a negative regulator of EGF-induced mitogenic proliferation in neuroblastoma cells: T-cadherin-negative TGW and NH-12 neuroblastoma cells transfected with T-cadherin cDNA lost their mitogenic proliferative response to epidermal growth factor. Stable transfection of T-cadherin cDNA into T-cadherin-negative neuroblastoma cell lines, proliferation assay Journal of neurochemistry Medium 10737605
2001 CDH13 (T-cadherin) expression downregulates surfactant protein D (SP-D) gene expression in human bronchioloalveolar type-II cells: A549 cells transfected with T-cadherin cDNA lost SP-D mRNA and protein expression, while control-transfected cells retained SP-D expression. Stable transfection of T-cadherin expression vector into A549 cells; RT-PCR and Western blot for SP-D Virchows Archiv Medium 11355171
2001 CDH13 (T-cadherin) is a GPI-anchored cadherin lacking a cytoplasmic domain and transmembrane region, anchored to the cell surface membrane through a glycosyl phosphatidyl inositol moiety. Biochemical characterization, structural analysis reviewed Histology and histopathology Medium 11642747
2001 CDH13 promoter methylation causes biallelic silencing of CDH13 expression in breast and lung cancer cell lines; demethylation with 5-aza-2-deoxycytidine restores CDH13 mRNA expression, confirming that promoter hypermethylation is a direct mechanism of CDH13 gene silencing. Methylation-specific PCR, RT-PCR, 5-aza-2-deoxycytidine demethylation treatment in cancer cell lines Cancer research High 11389090
2002 CDH13 promoter methylation combined with loss of heterozygosity causes loss of CDH13 expression in invasive cutaneous squamous cell carcinoma; demethylation with 5-aza-2-deoxycytidine restores T-cadherin expression in A431 cells with aberrant methylation. LOH analysis, methylation-specific PCR, sequence analysis, 5-aza-2-deoxycytidine treatment, immunohistochemistry, Western blot Laboratory investigation High 12177241
2012 BRN2 (POU3F2/N-Oct-3) is a direct transcriptional repressor of CDH13 in melanoma cells: BRN2 binds to the CDH13 promoter at a regulatory element (-219 bp, sequence 5'-CATGCAAAA-3') and represses CDH13 promoter activity; BRN2 overexpression suppresses CDH13, while BRN2 knockdown restores T-cadherin expression. Reporter gene (luciferase) assay, electrophoretic mobility shift assay (EMSA), ectopic expression and siRNA knockdown of BRN2 in melanoma cells, RT-PCR, Western blot Laboratory investigation High 23069940
2013 CDH13 (T-cadherin) functions as a pro-apoptotic tumor suppressor in melanoma by antagonizing AKT/CREB/AP-1/FoxO3a signaling: T-cadherin expression induces AKT and FoxO3a hypophosphorylation, downregulates BCL-2, BCL-xL, and Clusterin, and reduces CREB and AP-1 transcriptional activity, sensitizing cells to CD95/Fas-mediated apoptosis. NFκB, TCF/LEF, and mTOR are not part of T-cadherin signaling. Stable CDH13 expression in melanoma cells, tumor xenograft in nude mice, Western blot (pAKT, pFoxO3a, BCL-2, BCL-xL, Clusterin), reporter gene assay (CREB, AP-1, NFκB, TCF/LEF, mTOR), apoptosis assay with CD95/Fas antibody Molecular carcinogenesis High 23625515
2011 CDH13 (T-cadherin) associates with insulin granules in pancreatic β-cells and is required for second-phase glucose-induced insulin secretion: T-cadherin was found on insulin granules by immunohistochemistry and electron microscopy; T-cadherin-deficient (Tcad-KO) mice showed impaired glucose-induced but not KCl-mediated insulin secretion in vitro, and defective second-phase insulin release during hyperglycemic clamp in vivo, leading to progressive glucose intolerance. Immunohistochemistry, electron microscopy, RFP-tagged T-cadherin colocalization with GFP-labeled insulin granules, Tcad-KO mouse phenotyping, in vitro islet insulin secretion assay, in vivo hyperglycemic clamp Islets High 21975561
2011 T-cadherin deficiency (T-cad KO) protects against OVA-induced allergic airway hyperresponsiveness and inflammation; the protective effect requires adiponectin, as combined adiponectin/T-cad bideficiency reverses it; T-cad KO elevates circulating adiponectin levels because adiponectin normally sequestered by endothelial T-cad remains free in circulation. T-cad KO and adiponectin/T-cad bideficient mouse models, OVA sensitization and challenge, airway hyperresponsiveness measurement, BAL cell counting, cytokine/eotaxin mRNA, lung histology, serum adiponectin ELISA PloS one High 22815927
2013 T-cadherin binding to adiponectin (specifically HMW isoforms) via endothelial T-cadherin is required for suppression of ozone-induced IL-17A expression and pulmonary inflammation: T-cad KO mice showed augmented IL-17A induction by ozone, and T-cad/Adipo double-KO showed no further increase compared to T-cad KO alone, establishing T-cad as required mediator of adiponectin's suppression of IL-17A in the lung. Genetic epistasis with T-cad KO, Adipo KO, and T-cad/Adipo double-KO mice; ozone exposure; pulmonary IL-17A, saa3 mRNA; BAL neutrophils; G-CSF; lung histology PloS one High 23755285
2013 CDH13 missense variants found in ADHD patients are processed canonically as GPI-anchored proteins; wild-type and mutant CDH13 proteins showed similar expression levels and subcellular distribution in CHO and HEK293 cells, indicating no significant functional difference in processing or localization for these rare variants. Sequencing of CDH13 in ADHD patients and controls; GFP-tagged and native protein expression in CHO/HEK293 cells; immunofluorescence localization PloS one Medium 23936508
2012 CDH13 knockdown in bladder TCC 5637 cells promotes cell migration, invasion, adhesion, and upregulates MMP2 expression, establishing CDH13 as a suppressor of invasiveness in bladder cancer acting via MMP2 regulation. siRNA knockdown of CDH13 in 5637 bladder cancer cells; migration/invasion/adhesion assays; RT-PCR and Western blot for MMP2; IHC in primary tumor tissues Urologia internationalis Medium 23235385
2015 The UHRF1/PRMT5 complex contributes to CDH13 promoter methylation in endometrial carcinoma: Co-immunoprecipitation demonstrated PRMT5 binds UHRF1; combined 5-Aza-CdR and TSA treatment completely reversed CDH13 methylation and restored expression, while either agent alone only partially reversed it. Co-immunoprecipitation (UHRF1-PRMT5 interaction), methylation-specific PCR, qRT-PCR, 5-Aza-CdR and TSA treatment of endometrial carcinoma cell lines Gynecologic oncology Medium 26597461
2018 microRNA-377 directly targets CDH13 mRNA: dual-luciferase reporter assay confirmed miR-377 binds the CDH13 3'-UTR; miR-377 knockdown in an Alzheimer's disease cell model increased CDH13 expression and reduced cell viability, while CDH13 knockdown reversed these effects. Dual-luciferase reporter gene assay, qRT-PCR, Western blot, CCK-8 viability assay, flow cytometry apoptosis assay in SH-SY5Y cells European review for medical and pharmacological sciences Medium 29771432
2018 CDH13 modulates lipid metabolism during adipogenesis but not in mature adipocytes: CDH13 knockdown during adipogenesis reduced fatty acid uptake, lipid content, and blunted induction of PPARγ and C/EBPα expression in 3T3-L1 adipocytes. CDH13 knockdown in 3T3-L1 adipocytes during differentiation; fatty acid uptake assay; lipid content measurement; RT-PCR/Western blot for PPARγ and C/EBPα International journal of obesity Medium 29467502
2020 DNA polymerase β (Pol β) promotes CDH13 expression through demethylation of the CDH13 promoter via its role in base excision repair; CDH13 mediates the anti-migratory and anti-invasive effects of Pol β in breast and lung cancer cells, as CDH13 knockdown rescues migration, invasion, and angiogenesis suppressed by Pol β overexpression. Pol β overexpression and knockdown in breast/lung cancer cells; CDH13 mRNA/protein measurement; CDH13 promoter methylation analysis; migration/invasion assays; mouse xenograft tumor model; CDH13 siRNA rescue experiment Oncogene Medium 32641859
2018 CDH13 deficiency in mice leads to increased inhibitory drive onto hippocampal CA1 pyramidal neurons, a shift in excitatory/inhibitory balance, and moderates migration of serotonergic neurons in the dorsal raphe nucleus preferentially projecting to thalamus and cerebellum; CDH13 knockout mice show impaired fear extinction and increased stress-related behavioral phenotypes. Cdh13 knockout (KO, heterozygous, homozygous) mice; behavioral battery (Barnes maze, fear conditioning, light-dark test, locomotor); hippocampal transcriptome analysis; inference from electrophysiology data cited in abstract Progress in neuro-psychopharmacology & biological psychiatry Medium 30165120
2024 CDH13 (T-cadherin) interacts with MyD88 as shown by molecular docking simulations and co-immunoprecipitation; pharmacological treatment with PDA upregulates MyD88 in smooth muscle cells and interacts with CDH13, augmenting SMC proliferation, migration, and extracellular matrix deposition, culminating in pathological vascular remodeling. Molecular docking, co-immunoprecipitation, smooth muscle cell proliferation assay (BrdU), Boyden chamber migration assay, spheroid sprouting assay, Matrigel tube formation, carotid artery ligation mouse model Chinese journal of natural medicines Medium 38278560
2024 CDH13 expression promotes melanoma cell sensitivity to garcinol-induced apoptosis: garcinol reduced proliferation and induced apoptosis more effectively in CDH13-positive melanoma cells; siRNA knockdown of CDH13 reduced garcinol sensitivity and restored proliferation and anti-apoptotic behavior. siRNA knockdown of CDH13 in melanoma cell lines; proliferation assay; apoptosis assay; garcinol treatment Cancers Medium 38791932
2024 CDH13 activation via small activating RNA (saRNA) in imatinib-resistant CML cells inhibits NF-κB signaling pathway and induces apoptosis, overcoming BCR-ABL1-independent imatinib resistance; LNP-delivered saRNA also limited K562-IMR tumor growth in vivo. saRNA design targeting CDH13 promoter; qPCR and Western blot for CDH13 expression; cell viability and colony formation assays; NF-κB pathway activity measurement; mouse xenograft model with LNP-saRNA Cell death & disease Medium 39179585
2025 CDH13 mRNA stability is regulated by the lncRNA CDH13-AS2, which binds CDH13 mRNA in endothelial cells and protects it from miRNA-mediated degradation; miRNAs miR-19b-3p, miR-125b-2-3p, miR-433-3p, and miR-7b-5p accelerate CDH13 mRNA degradation, an effect neutralized by CRISPRa activation of CDH13-AS2. CDH13 loss of function increases atherosclerotic plaque size in Cdh13/Apoe double-KO mice on a Western diet. dCas13-mediated RNA immunoprecipitation (CDH13-AS2 binding to CDH13 mRNA), CRISPR/Cas9 KO and CRISPRa of CDH13-AS2 in human endothelial cells, miRNA screen, Cdh13/Apoe double-KO mouse model with Western diet, UK Biobank LoF variant analysis Research square (preprint)preprint Medium 40894025
2026 CDH13 is expressed in endothelial cells of pathological neovascular membranes; CDH13 knockdown inhibits pathological vessel growth and promotes vascular normalization in OIR and CNV mouse models; mechanistically, hypoxia suppresses NR2F2, de-repressing CDH13 transcription and activating NF-κB to drive vascular dysfunction; CDH13 inhibition with LXR agonist GW3965 reduced LDL deposition and pathological neovascularization. CDH13 knockdown in OIR/CNV mouse models; in vitro transwell, wound healing, EdU assays; dual-luciferase reporter assay (NR2F2-CDH13 axis); RT-PCR, Western blot; fundus fluorescein angiography; isolectin B4 staining; bioinformatics of human nAMD FVMs Journal of translational medicine Medium 41814412

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2001 Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer research 210 11389090
2000 Expression of T-cadherin (CDH13, H-Cadherin) in human brain and its characteristics as a negative growth regulator of epidermal growth factor in neuroblastoma cells. Journal of neurochemistry 161 10737605
2009 Genome-wide scan identifies CDH13 as a novel susceptibility locus contributing to blood pressure determination in two European populations. Human molecular genetics 140 19304780
1998 The H-cadherin (CDH13) gene is inactivated in human lung cancer. Human genetics 138 9737784
2002 Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas. Cancer research 117 12067979
2011 Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. The Journal of pathology 116 21710692
2007 Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 91 17873891
2012 Impact of the ADHD-susceptibility gene CDH13 on development and function of brain networks. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 77 22795700
1999 Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer. International journal of oncology 72 10493953
2001 Recent progress in T-cadherin (CDH13, H-cadherin) research. Histology and histopathology 65 11642747
2011 CDH13 gene coding T-cadherin influences variations in plasma adiponectin levels in the Japanese population. Human mutation 64 22065538
2005 Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma. Cancer 62 16177988
2006 p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. Journal of cellular physiology 61 16222700
2002 Loss of T-cadherin (CDH13, H-cadherin) expression in cutaneous squamous cell carcinoma. Laboratory investigation; a journal of technical methods and pathology 60 12177241
2004 CDH13 promoter region is specifically methylated in poorly differentiated colorectal cancer. British journal of cancer 59 14997203
2008 Aneuploidy predicts outcome in patients with endometrial carcinoma and is related to lack of CDH13 hypermethylation. Clinical cancer research : an official journal of the American Association for Cancer Research 52 18519763
2015 Methylation of tumor suppressor gene CDH13 and SHP1 promoters and their epigenetic regulation by the UHRF1/PRMT5 complex in endometrial carcinoma. Gynecologic oncology 51 26597461
2008 Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors. International journal of cancer 50 18729198
2006 Aberrant methylation of CDH13 gene in nasopharyngeal carcinoma could serve as a potential diagnostic biomarker. Oral oncology 49 16807071
2004 Frequent promoter methylation and gene silencing of CDH13 in pancreatic cancer. Cancer science 49 15245595
2012 Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC cancer 45 22695491
2013 Genetic variation in CDH13 is associated with lower plasma adiponectin levels but greater adiponectin sensitivity in East Asian populations. Diabetes 44 24009259
2004 Methylation pattern of CDH13 gene in digestive tract cancers. British journal of cancer 44 15292927
2011 CDH13 is associated with working memory performance in attention deficit/hyperactivity disorder. Genes, brain, and behavior 43 21815997
2012 Role of the adiponectin binding protein, T-cadherin (Cdh13), in allergic airways responses in mice. PloS one 41 22815927
2011 A variant upstream of the CDH13 adiponectin receptor gene and metabolic syndrome in Swedes. The American journal of cardiology 36 21872196
2010 Promoter hypermethylation of CDH13, DAPK1 and TWIST1 genes in precancerous and cancerous lesions of the uterine cervix. Pathology, research and practice 30 21129853
2015 Association of CDH13 genotypes/haplotypes with circulating adiponectin levels, metabolic syndrome, and related metabolic phenotypes: the role of the suppression effect. PloS one 29 25875811
2011 T-cadherin (Cdh13) in association with pancreatic β-cell granules contributes to second phase insulin secretion. Islets 28 21975561
2011 Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathologic characteristics of primary non-small-cell lung carcinoma. Clinical lung cancer 28 22169480
2014 CDH13 promoter SNPs with pleiotropic effect on cardiometabolic parameters represent methylation QTLs. Human genetics 27 25543204
2012 Clinical relevance of CDH1 and CDH13 DNA-methylation in serum of cervical cancer patients. International journal of molecular sciences 26 22942707
2011 Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma. The Journal of international medical research 26 21672320
2018 CDH13 promoter methylation regulates cisplatin resistance of non-small cell lung cancer cells. Oncology letters 25 30344726
2016 Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma. Journal of Cancer 25 27994665
2014 Methylation of RASSF1A and CDH13 genes in individualized chemotherapy for patients with non-small cell lung cancer. Asian Pacific journal of cancer prevention : APJCP 25 24998565
2018 Regulatory mechanism of microRNA-377 on CDH13 expression in the cell model of Alzheimer's disease. European review for medical and pharmacological sciences 24 29771432
2018 Early-life stress impairs developmental programming in Cadherin 13 (CDH13)-deficient mice. Progress in neuro-psychopharmacology & biological psychiatry 24 30165120
2001 T-cadherin (CDH13, H-cadherin) expression downregulated surfactant protein D in bronchioloalveolar cells. Virchows Archiv : an international journal of pathology 24 11355171
2013 Functional properties of rare missense variants of human CDH13 found in adult attention deficit/hyperactivity disorder (ADHD) patients. PloS one 23 23936508
2012 BRN2 is a transcriptional repressor of CDH13 (T-cadherin) in melanoma cells. Laboratory investigation; a journal of technical methods and pathology 23 23069940
2018 CDH13 abundance interferes with adipocyte differentiation and is a novel biomarker for adipose tissue health. International journal of obesity (2005) 22 29467502
2020 DNA polymerase beta modulates cancer progression via enhancing CDH13 expression by promoter demethylation. Oncogene 21 32641859
2013 CDH13 genotype-dependent association of high-molecular weight adiponectin with all-cause mortality: the J-SHIPP study. Diabetes care 21 24041676
2008 Microarray comparative genomic hybridization analysis of tubular breast carcinoma shows recurrent loss of the CDH13 locus on 16q. Human pathology 21 18656243
2013 Loss of T-cadherin (CDH-13) regulates AKT signaling and desensitizes cells to apoptosis in melanoma. Molecular carcinogenesis 20 23625515
2014 Aberrant methylation of CDH13 is a potential biomarker for predicting the recurrence and progression of non muscle invasive bladder cancer. Medical science monitor : international medical journal of experimental and clinical research 19 25196672
2015 CDH13 Polymorphisms are Associated with Adiponectin Levels and Metabolic Syndrome Traits Independently of Visceral Fat Mass. Journal of atherosclerosis and thrombosis 18 26423718
2004 Prevalent hyper-methylation of the CDH13 gene promoter in malignant B cell lymphomas. International journal of oncology 18 15289870
2021 A Common CDH13 Variant Is Associated with Low Agreeableness and Neural Responses to Working Memory Tasks in ADHD. Genes 16 34573337
2020 APOB Genotypes and CDH13 Haplotypes in the Cholesterol-Related Pathway Genes Predict Non-Small Cell Lung Cancer Survival. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 16 32238407
2018 Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer. Journal of biomedical research 16 30355852
2016 Hypermethylation of CDH13, DKK3 and FOXL2 promoters and the expression of EZH2 in ovary granulosa cell tumors. Molecular medicine reports 16 27431680
2018 Interactions of CDH13 gene polymorphisms and ambient PM10 air pollution exposure with blood pressure and hypertension in Korean men. Chemosphere 15 30476760
2017 Cdh13 and AdipoQ gene knockout alter instrumental and Pavlovian drug conditioning. Genes, brain, and behavior 14 28387990
2013 Role of the adiponectin binding protein, T-cadherin (cdh13), in pulmonary responses to subacute ozone. PloS one 14 23755285
2012 Downregulation of CDH13 expression promotes invasiveness of bladder transitional cell carcinoma. Urologia internationalis 14 23235385
2013 Association between CDH13 variants and cardiometabolic and vascular phenotypes in a Korean population. Yonsei medical journal 12 24142632
2016 Clinical significance of CDH13 promoter methylation as a biomarker for bladder cancer: a meta-analysis. BMC urology 11 27578166
2016 The T>A (rs11646213) gene polymorphism of cadherin-13 (CDH13) gene is associated with decreased risk of developing hypertension in Mexican population. Immunobiology 11 27682011
2015 CDH13 and HCRTR2 May Be Associated with Hypersomnia Symptom of Bipolar Depression: A Genome-Wide Functional Enrichment Pathway Analysis. Psychiatry investigation 11 26207136
2018 Loss of Cardio-Protective Effects at the CDH13 Locus Due to Gene-Sleep Interaction: The BCAMS Study. EBioMedicine 10 29903569
2016 CDH13 gene-by-PM10 interaction effect on lung function decline in Korean men. Chemosphere 10 27839881
2015 Variants in SELL, MRPS36P2, TP63, DDB2, CACNA1H, ADAM19, GNAI1, CDH13 and GABRG2 interact to confer risk of acne in Chinese population. The Journal of dermatology 10 25573302
2015 Quantitative assessment of the diagnostic role of CDH13 promoter methylation in lung cancer. Asian Pacific journal of cancer prevention : APJCP 9 25735345
2021 Familial Psychosis Associated With a Missense Mutation at MACF1 Gene Combined With the Rare Duplications DUP3p26.3 and DUP16q23.3, Affecting the CNTN6 and CDH13 Genes. Frontiers in genetics 8 33897758
2016 Chromosome 16q genes CDH1, CDH13 and ADAMTS18 are correlated and frequently methylated in human lymphoma. Oncology letters 8 27900031
2009 [Methylation status of JunB and CDH13 gene promoter in CD34(+)CD38(-) chronic myelogenous leukemia cells]. Zhongguo shi yan xue ye xue za zhi 8 20030915
2025 T-Cadherin (CDH13) and Non-Coding RNAs: The Crosstalk Between Health and Disease. International journal of molecular sciences 7 40649905
2022 Hsa_circ_0000119 promoted ovarian cancer development via enhancing the methylation of CDH13 by sponging miR-142-5p. Journal of biochemical and molecular toxicology 7 36482494
2020 CDH13 and LPHN3 Gene Polymorphisms in Attention-Deficit/Hyperactivity Disorder: Their Relation to Clinical Characteristics. Journal of molecular neuroscience : MN 7 32691279
2016 Genetic variants of CDH13 determine the susceptibility to chronic obstructive pulmonary disease in a Chinese population. Acta pharmacologica Sinica 7 26806298
1998 A GT dinucleotide repeat polymorphism in intron 1 of the H-cadherin (CDH13) gene. Journal of human genetics 7 9852687
2024 The Role of T-Cadherin (CDH13) in Treatment Options with Garcinol in Melanoma. Cancers 6 38791932
2020 Relationship between Methylation of FHIT and CDH13 Gene Promoter Region and Liver Cancer. Current medical science 6 32474857
2016 The effect of celecoxib on DNA methylation of CDH13, TFPI2, and FSTL1 in squamous cell carcinoma of the esophagus in vivo. Anti-cancer drugs 6 27400374
2015 Revealing the Strong Functional Association of adipor2 and cdh13 with adipoq: A Gene Network Study. Cell biochemistry and biophysics 6 25388841
2014 Association study of ARL15 and CDH13 with T2DM in a Han Chinese population. International journal of medical sciences 6 24688318
2005 T-/H-cadherin (CDH13): a new marker for differentiating podocytes. Virchows Archiv : an international journal of pathology 6 16133358
2024 Potassium dehydroandrographolide succinate regulates the MyD88/CDH13 signaling pathway to enhance vascular injury-induced pathological vascular remodeling. Chinese journal of natural medicines 5 38278560
2024 Droplet digital PCR analysis of CDH13 methylation status in Slovak women with invasive ductal breast cancer. Scientific reports 5 38926485
2015 Differential Associations between CDH13 Genotypes, Adiponectin Levels, and Circulating Levels of Cellular Adhesive Molecules. Mediators of inflammation 5 26600672
2016 Pharmacogenetics of stimulant abuse liability: association of CDH13 variant with amphetamine response in a racially-heterogeneous sample of healthy young adults. Psychopharmacology 4 27771748
2010 Methylation of cyclin-dependent kinase inhibitors, XAF1, JUNB, CDH13 and soluble Wnt inhibitors in essential thrombocythaemia. Journal of clinical pathology 4 20364027
2024 Analysis of CDO1, PITX2, and CDH13 Gene Methylation in Early Endometrial Cancer for Prediction of Medical Treatment Outcomes. International journal of molecular sciences 3 38732110
2021 Interactive association between dietary fat and sex on CDH13 cg02263260 methylation. BMC medical genomics 3 33407434
2017 The association of six single nucleotide polymorphisms and their haplotypes in CDH13 with T2DM in a Han Chinese population. Medicine 3 28562572
2017 Genetic variation in CDH13 gene was associated with non-small cell lung cancer (NSCLC): A population-based case-control study. Oncotarget 3 29416663
2012 [5-aza-2'-deoxycytidine-induced inhibition of CDH13 expression and its inhibitory effect on methylation status in human colon cancer cells in vitro and on growth of xenograft in nude mice]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 3 22490847
2024 Small RNA activation of CDH13 expression overcome BCR-ABL1-independent imatinib-resistance and their signaling pathway studies in chronic myeloid leukemia. Cell death & disease 2 39179585
2023 Association of the CDH13 gene variant rs9940180 with schizophrenia risk in North Indian population. American journal of translational research 2 38074818
2025 An interplay of non-coding RNAs regulates CDH13 expression and affects endothelial function and coronary artery disease risk. Research square 1 40894025
2019 A potential role for the CDH13/CDH15 gene in repeat revascularization after first percutaneous coronary intervention. Pharmacogenomics 1 31854260
2015 [Single Nucleotide Polymorphisms in T-Cadherin Gene (CDH13) Have Cumulative Effect on Body Mass in Patients With Ischemic Heart Disease]. Kardiologiia 1 27125099
2026 Targeting CDH13 as a therapeutic strategy to mitigate pathological ocular angiogenesis. Journal of translational medicine 0 41814412
2026 Association Between CDH13 rs12596316 and Adiponectin Levels According to Fasting Glucose Status in a Korean Population. Genes 0 41898868
2025 Multimodal analysis reveals potential association of CDH13 with endothelial cells and its overexpression in hepatocellular carcinoma. European journal of medical research 0 41388436
2021 Association of CDH13 Gene Polymorphism and Metabolic Syndrome in Gambian Population. Medical archives (Sarajevo, Bosnia and Herzegovina) 0 34759445
2018 [Association of single nucleotide polymorphisms of CDH13 gene with metabolic syndrome among ethnic Han Chinese]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 0 29419874
2009 [Expression of the CDH13 gene and BCR/ABL fusion gene in chronic myeloid leukemia patients and their relationship]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 0 19199263

Missed literature

Know a paper Affinage missed for CDH13? Flag it for the maintainers and the community.

No submissions yet.